John Le Gall MD

Chief Medical Officer

Dr Le Gall is a board-certified pediatric hematologist-oncologist with more than a decade of experience in cell therapy across hematologic malignancies and solid tumors. Most recently, he was Vice President, Head of Clinical Development at Allogene Therapeutics, leading the company’s allogeneic CAR-T portfolio from early clinical studies through pivotal development. He previously held clinical development leadership roles at Instil Bio and at Kite, a Gilead company. Dr Le Gall holds an MD and MBA from Columbia University.